Blogs
Fri Jul 18, 5:07 PM
Fri Jul 18, 3:14 PM
Fri Jul 18, 6:11 PM
Fri Jul 18, 3:43 AM
Fri Jul 18, 5:46 PM
Fri Jul 18, 2:46 PM
Fri Jul 18, 4:03 AM
Thu Jul 17, 4:58 PM
Thu Jul 17, 11:30 AM
Thu Jul 17, 4:18 AM
Thu Jul 17, 3:10 PM
Wed Jul 16, 5:03 PM
Recent Articles
Recent Articles by Ben Palosaari
No related articles found
National Features >
Houston Press
What mainstream publishers don't want you to know about door-to-door magazine sales.
By Craig Malisow
Riverfront Times
When these huntresses on are on the prowl, the prey very much wants to be caught.
By Unreal
Broward-Palm Beach New Times
How rumored McCain veep choice Charlie Crist wants to bail out Big Sugar.
By Bob Norman
SF Weekly
Are Asian women getting their jawbones cut to look whiter?
By Lauren Smiley
M.E. Smith
Published on April 02, 2008
Husband-wife author duo Matt and Erin Smith, writing under a single name, do for the pharmaceutical industry what John Grisham did for law. In their novel, Trials: The Risk/Benefit Ratio, the local writers tell the story of Grant Adams, a researcher whose daughter is ill with bronchiosclerosis. Grant takes a job with a small Minnesota pharmaceutical company that just happens to be developing a new "miracle drug" and looking for trial participants. But Grant soon discovers that the company is steeped in sinister ambition. He becomes tangled among professional and moral research violations, and murder. The authors tell the story of the money-hungry few on top of the drug industry, willing to bend any rule and stake any life to get a drug on the market. While the company makes plans to transition to public ownership and earn more and more money, Smith follows a family whose son's lungs thicken, harden, and eventually succumb to the illness. As Grant investigates his employers more deeply, the facts get uglier, and ultimately he is left with a choice: blow the whistle on a corrupt company, or shut up and hope his daughter benefits from the drug trial. Who knew prescription drug research could be so thrilling?
Thu., April 3, 4 p.m., 2008